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Abstract
Introduction: Data on pulmonary complications in renal transplant recipients are scarce. The aim of this study was
to evaluate acute respiratory failure (ARF) in renal transplant recipients.
Methods: We conducted a retrospective observational study in nine transplant centers of consecutive kidney
transplant recipients admitted to the intensive care unit (ICU) for ARF from 2000 to 2008.
Results: Of 6,819 kidney transplant recipients, 452 (6.6%) required ICU admission, including 200 admitted for ARF.
Fifteen (7.5%) of these patients had combined kidney-pancreas transplantations. The most common causes of ARF
were bacterial pneumonia (35.5%), cardiogenic pulmonary edema (24.5%) and extrapulmonary acute respiratory
distress syndrome (ARDS) (15.5%). Pneumocystis pneumonia occurred in 11.5% of patients. Mechanical ventilation
was used in 93 patients (46.5%), vasopressors were used in 82 patients (41%) and dialysis was administered in 104
patients (52%). Both the in-hospital and 90-day mortality rates were 22.5%. Among the 155 day 90 survivors, 115
patients (74.2%) were dialysis-free, including 75 patients (65.2%) who recovered prior renal function. Factors
independently associated with in-hospital mortality were shock at admission (odds ratio (OR) 8.70, 95% confidence
interval (95% CI) 3.25 to 23.29), opportunistic fungal infection (OR 7.08, 95% CI 2.32 to 21.60) and bacterial infection
(OR 2.53, 95% CI 1.07 to 5.96). Five factors were independently associated with day 90 dialysis-free survival: renal
Sequential Organ Failure Assessment (SOFA) score on day 1 (OR 0.68/SOFA point, 95% CI 0.52 to 0.88), bacterial
infection (OR 0.43, 95% CI 0.21 to 0.90), three or four quadrants involved on chest X-ray (OR 0.44, 95% CI 0.21 to
0.91), time from hospital to ICU admission (OR 0.98/day, 95% CI 0.95 to 0.99) and oxygen flow at admission (OR
0.93/liter, 95% CI 0.86 to 0.99).
Conclusions: In kidney transplant recipients, ARF is associated with high mortality and graft loss rates. Increased
Pneumocystis and bacterial prophylaxis might improve these outcomes. Early ICU admission might prevent graft
loss.
Introduction
Kidney transplants account for about two-thirds of all
solid organ transplants [1]. In patients with end-stage
renal disease, kidney transplantation improves quality of
life and overall survival at a lower cost than kidney dia-
lysis [2]. Over the past two decades, the development of
new immunosuppressive drugs [3] and advances in the
understanding of drug management and immune modu-
lation have reduced the incidence of acute rejection epi-
sodes and have significantly improved long-term
outcomes [3-8]. The 10-year graft survival rate is now
greater than 60% [1,9].
These advances have prompted increased use of
kidney transplantation and substantial broadening of
eligibility criteria for both donors and recipients [10-14].
It has been estimated that in 2006, 103,312 patients
were living with a functional renal allograft in the
United States [15]. In transplant recipients, long-term
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pressive therapy used to prevent graft rejection carries a
risk of infection, cancer and drug-related toxicities
[16-19]. High-dose immunosuppressive therapy for
acute rejection episodes significantly increases these life-
threatening complications [16,19,20]. Furthermore, in
addition to long history of chronic renal disease and dia-
lysis, kidney transplant recipients often have severe
comorbidities (for example, cardiovascular disease and
diabetes) that are associated with specific immune defi-
ciencies [2]. This combination of problems leads to
complications, many of which involve the lungs [21,22].
In particular, renal transplant recipients may be at
increased risk for acute lung injury (ALI) and acute
respiratory distress syndrome (ARDS), most notably in
the event of graft failure or antilymphocyte globulin
therapy for rejection [23]. Moreover, opportunistic
pneumonia is among the leading causes of death in kid-
ney transplant recipients [24,25]. Although acute
respiratory failure (ARF) compromises short- and long-
term outcomes [22], few studies have assessed the need
for intensive care unit (ICU) management in kidney
transplant recipients with ARF.
The objective of this study was to identify determi-
nants of survival and graft function in kidney transplant
recipients admitted to the ICU for ARF. We assessed in-
hospital mortality and graft function 3 months after ICU
discharge [9,26].
Materials and methods
The ethics committee of the French Society for Critical
Care approved this retrospective noninterventional study
a n dw a i v e dt h en e e df o ri n f o r m e dc o n s e n t .T h es t u d y
was carried out in eight medical ICUs that admit
patients from nine transplant centers.
All adult recipients of a kidney or combined kidney
and pancreas transplant admitted to the ICU between
1 January 2000 and 1 August 2008 were screened.
Among them, we included those admitted for ARF,
defined as severe dyspnea at rest, respiratory rate greater
than 30 breaths per minute or clinical signs of respira-
t o r yd i s t r e s sa n do x y g e ns a t u r a t i o nl e s st h a n9 2 %o r
partial pressure of oxygen in arterial blood less than 60
mmHg on room air [27].
The data reported in Tables 1, 2 and 3 were
abstracted from the patients’ medical charts. Life-
sustaining treatments (that is, noninvasive or invasive
mechanical ventilation, renal replacement therapy, vaso-
pressors) were instituted at the discretion of the attend-
ing physicians. Criteria for noninvasive and endotracheal
mechanical ventilation were also determined by the dis-
cretion of the attending physicians.
In all patients, the diagnostic strategy implemented at
t h et i m eo fI C Ua d m i s s i o ni n cluded noninvasive tests
(that is, echocardiography, high-resolution computed
tomography, blood cultures, sputum examination, urine
and serum antigens, polymerase chain reaction assay for
cytomegalovirus, and Aspergillus antigenemia) with or
without fiberoptic bronchoscopy and bronchoalveolar
lavage (FO-BAL) [28,29]. The decision to perform FO-
BAL was at the discretion of the attending physicians.
Disease severity was assessed using the Sequential
Organ Failure Assessment (SOFA) score at admission
and during the first 3 days in the ICU. Data regarding
ICU and hospital lengths of stay, as well as survival sta-
tus at ICU and hospital discharges and on day 90 after
ICU discharge, were available for all patients. Graft sur-
vival (that is, patient survival without dialysis) 90 days
after ICU discharge was also recorded for survivors.
Statistical analysis
The statistical results are expressed as medians (25th to
75th percentiles) for quantitative variables or numbers
(percentages) for qualitative variables. The characteris-
tics of the patients and ARF episodes were compared
between hospital survivors and nonsurvivors using the
Wilcoxon rank-sum test or the Fisher’se x a c tt e s ta s
appropriate. To identify independent predictors of in-
hospital mortality, baseline characteristics that were sta-
tistically significant and clinically relevant were included
in a multivariable logistic regression model. A similar
analysis was conducted to identify independent predic-
tors of dialysis-free survival 90 days after ICU discharge.
Variables entered into both models are listed in Tables
5 and 6. In both multivariable logistic regression ana-
lyses, missing values were imputed via multiple imputa-
tions by using chained equations [30]. Log-linear effects
of continuous covariates were tested, calibration
w a st e s t e db yu s i n gt h el eC e s s i e - v a nH o u w e l i n g e n
goodness-of-fit test [31] and discrimination was assessed
by the C index, which is equivalent to the area under
the receiver-operating characteristic curve (AUROC)
[32]. All tests were two-sided, and P < 0.05 was consid-
ered statistically significant. Analyses were performed
using the R statistical package [33].
Results
Among the 6,919 patients who received kidney allografts
at the nine participating centers during the study period,
452 (6.6%) were admitted to the ICU, including 216
(47.8%) admitted for ARF. We report on the 200
patients with no missing data on day 90 (Figure 1).
Patient characteristics are reported in Table 1. Major
comorbidities were hypertension (82.8%), cardiovascular
disease (46.7%) and diabetes (27.6%). The three leading
causes of end-stage renal disease were glomerulonephri-
tis, diabetes mellitus and nephroangiosclerosis. Induc-
tion immunosuppressive treatment with antilymphocyte
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Page 2 of 10globulins or basiliximab was used in 94.1% of patients.
At ICU admission, all patients were receiving immuno-
suppressive therapy, usually with calcineurin inhibitors
(86%) combined with mycophenolate mofetil or
azathioprine (83.8%) and steroids (86.7%). Forty-three
patients (21.5%) had a history of acute rejection, which
occurred a median of 9.6 months (interquartile range
(IQR), 2.4 to 24.8) before ICU admission.
As shown in Table 2, the median time from kidney
transplantation to ICU admission was 17 months (IQR, 3
to 67.3). The median time from respiratory symptom
onset to ICU admission was 2 days (IQR, 1 to 6). At
admission, patients were severely hypoxemic with a med-
ian of 10 L/min oxygen flow ( I Q R ,6t o1 5 ) .R e s p i r a t o r y
symptoms included cough in 119 patients (59.8%), puru-
lent sputum in 31 patients (15.5%) and chest pain in 21
patients (10.5%). Hemoptysis was noted in six patients
(3%). In addition to ARF, 69 patients (34.8%) were in
shock at ICU admission. Laboratory findings indicated
poor graft function at ICU admission, with a median
serum creatinine level of 250 μM/(IQR, 156 to 382).
FO-BAL was performed in about one-half of the
patients (n = 113, 56.5%) and yielded the diagnosis in
45.5% of cases. Table 3 reports the clinical features and
outcomes according to the cause of ARF. Bacterial pneu-
monia was the most common diagnosis (n = 71, 35.5%),
with Escherichia coli and Streptococcus pneumoniae
being the most often recovered pathogens, but with
seven cases of methicillin-resistant Staphylococcus aureus
and five cases of Pseudomonas aeruginosa), followed by
cardiogenic pulmonary edema (n = 31, 24.5%) and ALI or
ARDS related to extrapulmonary bacterial sepsis. Oppor-
tunistic fungal infections were diagnosed in 29 patients,
including 23 patients with Pneumocystis jirovecii pneu-
monia, four with invasive aspergillosis, and two with
Candidemia. The cause of ARF remained unknown in
25 patients (12.5%). Table 4 reports the diagnoses of ARF
according to time after transplantation. In the early post-
transplant period (< 1 month), cardiogenic pulmonary
edema accounted for nearly one-half of the diagnoses,
while opportunistic fungal infections and drug-related
pulmonary toxicity were diagnosed mostly in the late
posttransplant period (> 6 months).
Noninvasive mechanical ventilation was required in 64
patients (32%) with 46.9% success, and invasive mechan-
ical ventilation was required in 93 patients (46.5%).
Table 1 Patient characteristics
a
Demographics All patients (N = 200) Hospital survivors (n = 155) Hospital deaths (n = 45) P value
Median age, yr (25th to 75th percentile) 56 (46 to 65) 55 (44 to 64) 61 (52 to 67) 0.06
Male sex, n (%) 123 (61.5) 97 (62.6) 26 (57.8) 0.60
Comorbidities, n (%)
Hypertension 164 (82.8) 130 (85) 35 (75.7) 0.18
Heart failure 93 (46.7) 73 (47.4) 20 (44.4) 0.74
Diabetes mellitus 55 (27.6) 41 (26.6) 14 (31.1) 0.57
Causes of end-stage renal disease, n (%) 0.7
Glomerulonephritis 52 (26) 41 (26.5) 11 (24.4)
Diabetes mellitus 29 (14.5) 21 (13.5) 8 (17.8)
Nephroangiosclerosis 24 (12) 19 (12.3) 5 (11.1)
Polycystic kidney disease 20 (10) 13 (8.4) 7 (15.6)
Uropathy 14 (7) 12 (7.7) 2 (4.4)
Other or undetermined 61 (30.5) 49 (31.6) 12 (26.7)
Characteristics of the transplantation, n (%) 0.28
First kidney allograft 147 (73.5) 116 (74.8) 31 (68.9)
Kidney retransplantation 38 (19) 26 (16.8) 12 (26.7)
Combined kidney-pancreas 15 (7.5) 13 (8.4) 2 (4.4)
Cadaver/living donor 190/8 (96/4) 148/7 (95.5/4.5) 44/1 (97.8/2.2) 0.69
Immunosuppressive regimen, n (%)
Cyclosporine 98 (50) 78 (51.3) 20 (45.5) 0.61
Tacrolimus 71 (36) 54 (35.3) 17 (38.6) 0.72
Mycophenolate mofetil 139 (71.6) 110 (72.8) 29 (67.4) 0.57
Sirolimus 25 (12.8) 21 (13.9) 4 (9.1) 0.61
Azathioprine 24 (12.2) 17 (11.2) 7 (15.9) 0.44
Steroids 170 (86.7) 132 (86.8) 38 (86.4) > 0.99
Acute rejection, n (%) 43 (21.5) 34 (21.9) 9 (20) 0.84
Cytomegalovirus disease, n (%) 37 (19.4) 27 (18.4) 10 (22.7) 0.52
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Page 3 of 10Vasopressors were needed in 82 patients (41%), and
renal replacement therapy was administered in 104
patients (52%).
As shown in Figure 1, ICU mortality was 18% (36
deaths), and in-hospital mortality was 22.5% (45 deaths).
On day 90 after ICU discharge, all 155 hospital survivors
were alive, and among them, 115 patients (74.2%) were
free of dialysis and 75 patients (65%) had recovered pre-
ICU level of kidney function.
As reported in Table 5, independent determinants of
in-hospital mortality were shock at ICU admission (odds
ratio (OR) 8.70, 95% confidence interval (95% CI) 3.25
to 23.29), diagnosis of opportunistic fungal infection
(OR 7.08, 95% CI 2.32 to 21.60) and diagnosis of bacter-
ial infection (OR 2.53, 95% CI 1.07 to 5.96).
Independent determinants of day 90 dialysis-free sur-
vival were worse renal SOFA score on day 1 (OR/SOFA
point 0.68, 95% CI 0.52 to 0.88), diagnosis of bacterial
infection (OR 0.43, 95% CI 0.21 to 0.90), lung infiltrates
in three or more quadrants on chest X-ray (OR 0.44,
95% CI 0.21 to 0.91), longer time from hospital to ICU
admission (OR/day 0.98, 95% CI 0.95 to 0.99) and oxy-
gen flow at ICU admission (OR per liter 0.93, 95% CI
0.86 to 0.99) (Table 6).
Discussion
We found that 6.6% of 6,819 kidney transplant recipi-
ents from nine transplant centers experienced acute ill-
nesses requiring ICU admission and that the reason for
ICU admission was ARF in about one-half of these
patients. Data collected 90 days after ICU discharge
showed that 22.5% of patients had died, 20% had lost
their transplant and returned to dialysis, 20% had
experienced deterioration in renal function and only
37.5% had recovered their pre-ICU renal function. Mor-
tality was associated not only with the severity of the
respiratory and hemodynamic manifestations but also
with the cause of ARF, with bacterial and fungal
Table 2 Characteristics of acute respiratory failure
a
Patient characteristics All patients
(N = 200)
Hospital survivors
(n = 155)
Hospital deaths
(n = 45)
P value
Median time from transplantation to ICU admission, months (25th to 75th
percentile)
17 (3 to 67.3) 17 (2 to 65) 15 (3 to 98) 0.69
Median time from acute rejection to ICU admission, months (25th to 75th
percentile) (n = 43 patients)
9.6 (2.8 to 23.8) 16.2 (3.6 to 40.8) 2.4 (0.4 to 7.2) 0.026
Median time from dyspnea onset to ICU admission, days (25th to 75th
percentile)
2 (1 to 6) 2 (1 to 6) 2 (0 to 7) 0.97
Median time from hospital to ICU admission, days (25th to 75th percentile) 3 (0 to 10) 2 (0 to 9) 3 (0 to 13) 0.69
Median body temperature at ICU admission (25th to 75th percentile) 38.5°C (37.2°C to
39.1°C)
38.5°C (37.2°C to
39.1°C)
38.5°C (37.2°C to
39.0°C)
0.57
PaO2/FiO2 ratio, n (%) 0.14
> 300 19 (10.9) 18 (13) 1 (3)
200-300 47 (26.9) 36 (27) 11 (28)
≤ 200 109 (62.3) 81 (60) 28 (70)
ICU admission directly from the emergency room, n (%) 61 (30.5) 46 (30) 15 (33) 0.71
Oxygen flow (L/minute) at ICU admission (25th to 75th percentile) 10 (6 to 15) 8 (5 to 15) 15 (6 to 15) 0.041
Serum creatinine (μM/L) at ICU admission (25th to 75th percentile) 250 (156 - 382) 255 (160 - 393) 240 (150 - 332) 0.23
Shock at ICU admission, n (%) 69 (34.8) 40 (26) 29 (64) < 0.0001
Need for life-sustaining treatments throughout ICU stay, n (%) < 0.0001
Respiratory support
Oxygen only 77 (38.5) 75 (48) 2 (4)
NIV 30 (15) 26 (17) 4 (9)
NIV followed by invasive mechanical ventilation 34 (17) 23 (15) 11 (24)
First-line invasive mechanical ventilation 59 (29.5) 31 (20) 28 (62)
Vasopressors 82 (41) 42 (27) 40 (89) < 0.0001
Renal replacement therapy 104 (52) 70 (45) 34 (76) 0.0006
Median SOFA score, day 1 7 (5 to 10) 6 (4 to 8) 11 (7 to 14) < 0.0001
Median SOFA score, day 2 6 (4 to 10) 5 (4 to 7) 12 (7 to 15) < 0.0001
Median SOFA score, day 3 5 (4 to 8) 5 (3 to 6) 12 (7 to 15) < 0.0001
Median length of ICU stay, days 6 (3 to 12) 5 (3 to 10) 8 (3 to 15) 0.25
Median length of hospital stay, days 22 (13 to 41) 22 (14 to 43) 23 (8 to 40) 0.27
aICU, intensive care unit; PaO2/FiO2 ratio, ratio of partial pressure of arterial oxygen to fraction of inspired oxygen; NIV, noninvasive mechanical ventilation; SOFA
score, Sequential Organ Failure Assessment score.
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Page 4 of 10Table 3 Characteristics of the pulmonary involvement according to the cause of acute respiratory failure
a
Cause Number
of
patients
Time (days) since
respiratory symptoms
onset
ARDS (PaO
2/FiO
2 ≤
200) at admission
Lung infiltration ≥3
quadrants on chest X-
ray
Shock at
admission
Mechanical
ventilation
Renal
replacement
therapy
Vasopressors Hospital
mortality
Day 90
dialysis-free
survival
All patients 200 2 (1 - 6) 109 (62.3) 69 (34.8) 93 (47) 82 (41) 104 (52) 45 (22.5) 115 (57.5)
Bacterial infection
Bacterial
pneumonia
71 2 (0 - 44) 39 (62) 27 (40) 39 (55) 44(62) 43 (61) 39 (55) 25 (35) 33 (47)
Extrapulmonary
ARDS
31 1 (0 - 20) 12 (48) 17 (57) 18 (58) 20 (65) 17 (55) 19 (61) 11 (36) 16 (52)
Cardiogenic
pulmonary edema
49 1 (0 - 29) 27 (64) 41 (85) 7 (15) 14 (29) 27 (55) 11 (22) 5 (10) 29 (59)
Opportunistic fungal
infection
Pneumocystis
pneumonia
23 10 (2 - 44) 18 (86) 20 (87) 0 (0) 12 (52) 14 (61) 9 (39) 7 (30) 11 (488)
Invasive
aspergillosis or
Candidemia
6 8 (0 - 45) 1 (33) 4 (67) 3 (50) 5 (83) 3 (50) 5 (83) 5 (83) 1 (17)
Viral pneumonia 6 5 (2 - 183) 2 (50) 3 (60) 0 (0) 2 (33) 1 (17) 0 (0) 0 (0) 5 (83)
Drug-related
pulmonary toxicity
6 12 (1 - 183) 4 (67) 5 (83) 1 (17) 5 (83) 4 (67) 3 (50) 1 (17) 3 (50)
Other 11 1 (0 - 30) 4 (36) 3 (27) 7 (64) 4 (36) 4 (36) 5 (46) 4 (36) 6 (55)
Undetermined 25 2 (0 - 8) 14 4 (17) 5 (21) 5 (20) 6 (24) 6 (24) 2 (8) 20 (80)
aData are expressed as number (%) or as median (25th to 75th percentile) for all patients and minimum-maximum for each diagnosis. A total of 203 diagnoses were made in 176 patients, and 25 patients (13%) had
no diagnosis. ARDS, acute respiratory distress syndrome; PaO
2/FiO
2 ratio, ratio of partial pressure of arterial oxygen to fraction of inspired oxygen.
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0pneumonia being associated with higher mortality rates.
Graft loss was associated with ARF severity, bacterial
infection and worse renal function at ICU admission.
Importantly, later ICU admission after hospital admis-
sion was associated with a higher risk of returning to
dialysis.
The ICU admission rate in our patients is in agree-
ment with rates reported in previous studies. In a sin-
gle-center study, the ICU admission rate was 6.4% [21],
and other studies have found rates of up to 25% [34,35]
overall and lower rates of admission for ARDS [23].
These differences may be related to differences in ICU
admission criteria and in medical complications. ARF
was consistently the leading reason for ICU admission
in our study. Among our patients with ARF, one-third
required noninvasive mechanical ventilation and nearly
one-half required endotracheal ventilation.
Transplant recipients are at increased risk for infec-
tion, drug toxicities and cancer [16,20]. Infection is the
leading reason for ICU admission and is significantly
associated with death [36]. ARF is probably most likely
to occur in kidney transplant recipients with high levels
of immunosuppression, as indicated in our study by the
high rate of previous acute rejection (21.5%), cytomega-
lovirus disease (18.5%) and retransplantation (19%). In
our patients, ARF was due to infection in two-thirds of
cases, and E. coli and S. pneumoniae were the most often
recovered bacteria. However, the noticeable rates of resis-
tant pathogens, such as methicillin-resistant S. aureus
and Pseudomonas spp., should be borne in mind when
choosing the first-line antibiotic regimen. Factors that
increase the risk of resistant organisms include high-level
exposure to the healthcare system during dialysis and
transplantation-related assessments. Invasive fungal
infections were associated with mortality in our study.
Candidiasis and aspergillosis are known to be associated
with very high mortality rates [24]. P. jirovecii pneumonia
was the leading cause of opportunistic infection in our
Table 6 Multivariable analysis: predictors of day 90
dialysis-free survival
a
Predictor variable Odds
ratio
95% confidence
interval
P
value
Renal SOFA score on day 1 (per
point on SOFA scale)
0.68 0.52 to 0.88 0.004
Bacterial infection 0.43 0.21 to 0.90 0.025
Lung infiltration ≥3 quadrants on
chest-X ray
0.44 0.21 to 0.91 0.027
Time from hospital to ICU
admission (per day)
0.98 0.95 to 0.99 0.045
Oxygen flow at admission (per liter) 0.93 0.86 to 0.99 0.048
Shock at admission 0.61 0.29 to 1.25 0.17
Sirolimus-based immunosuppressive
regimen
2.26 0.79 to 6.50 0.13
aArea under the receiver-operating characteristic curve = 0.77; Cessie van
Houwelingen goodness-of-fit test, P = 0.25; SOFA score, Sequential Organ
Failure Assessment score; ICU, intensive care unit.
Table 5 Multivariable analysis: predictors of in-hospital
mortality
a
Predictor of hospital mortality Odds
ratio
95% confidence
interval
P
value
Shock at ICU admission 8.70 3.25 to 23.29 0.00002
Opportunistic fungal infection
b 7.08 2.32 to 21.60 0.0007
Bacterial infection 2.53 1.07 to 5.96 0.034
Lung infiltration ≥3 quadrants
on chest-X ray
2.50 0.98 to 6.37 0.051
Extrapulmonary ARDS 2.30 0.83 to 6.38 0.11
Oxygen flow at ICU admission
(per liter)
1.05 0.97 to 1.15 0.24
aICU, intensive care unit; ARDS, acute respiratory distress syndrome; area
under the receiver-operating characteristic curve = 0.83; Cessie van
Houwelingen goodness-of-fit test, P = 0.45;
bPneumocystis pneumonia, invasive
aspergillosis, or Candidemia.
Table 4 Diagnosis of acute respiratory failure according to the delay between transplantation to ICU admission
a
Diagnosis Number of patients Time from transplantation to ICU admission
< 1 month 1 to 3 months 3 to 6 months > 6 months
All patients 200 27 (14%) 30 (15%) 14 (7%) 129 (65%)
Bacterial infection
Bacterial pneumonia 71 7 (24%) 15 (39%) 3 (19%) 46 (32%)
Extrapulmonary ARDS 31 3 (10%) 6 (15%) 4 (25%) 18 (13%)
Cardiogenic pulmonary edema 49 14 (48%) 7 (18%) 2 (13%) 26 (18%)
Opportunistic fungal infection
Pneumocystis pneumonia 23 0 3 (8%) 2 (13%) 18 (13%)
Invasive aspergillosis or Candidemia 6 0 2 (5%) 2 (13%) 2 (1%)
Viral pneumonia 6 0 3 (8%) 0 3 (2%)
Drug-related pulmonary toxicity 6 0 1 (3%) 0 5 (4%)
Other 11 2 (7%) 1 (3%) 0 8 (6%)
No diagnosis 25 3 (10%) 1 (3%) 3 (19%) 18 (13%)
aData are expressed as number of patients (%) and number of diagnoses (%). A total of 25 patients had no diagnosis. The 175 remaining patients had a total of
203 diagnoses. ICU, intensive care unit; ARDS, acute respiratory distress syndrome.
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Page 6 of 10study, despite routine trimethoprim-sulfamethoxazole
chemoprophylaxis as recommended [37]. However,
P. jirovecii pneumonia occurred late after transplantation,
at least 6 months after chemoprophylaxis was stopped.
This important finding suggests that a longer time on
chemoprophylaxis [38] may be appropriate in patients
selected on the basis of a history of transplantation, acute
rejection episode, pulse and chronic corticosteroid ther-
apy, graft function and immunosuppressive regimen
[25,39].
I C Um o r t a l i t yi no u rc o h o r tw a s1 8 % ,i nk e e p i n gw i t ht h e
findings of two earlier studies (10.6% [35] and 11% [40]).
T h e9 0 - d a ym o r t a l i t yr a t ew a s2 2 . 5 % ,w h i c hw a sl o w e r
than rates reported in earlier studies [21,22,34,35,40].
Figure 1 Flowchart of the study.
Canet et al. Critical Care 2011, 15:R91
http://ccforum.com/content/15/2/R91
Page 7 of 10Three other studies found substantially higher ICU mortal-
ity rates ranging from 36% to 58.8% [21,22,34]. These dif-
ferences may be related to several factors. The studies with
high mortality rates were single-center studies of small
numbers of patients who had greater disease severity at
ICU admission and higher SOFA scores (8.6 in the study
by Klouche et al. [21]) or greater use of life-sustaining
treatments. One study [22] included nosocomial pneumo-
nia occurring during the ICU stay among the causes of
ARF, and another [30] included mostly postsurgical
patients.
In our study, only 37.5% of patients recovered their
previous level of graft function, and 25.8% had to
resume dialysis. In a single-center study, graft loss
requiring resumption of renal replacement therapy was
present at ICU discharge in 14.7% of survivors [21]. In
keeping with our results, previous studies found that
pre-ICU renal function was a major determinant of graft
survival [26] and that ICU admission accelerated the
pace of renal function decline [9]. In our study, factors
associated with graft loss were worse renal SOFA score
at admission, bacterial infection, involvement of more
than three quadrants on the chest radiograph and longer
time from hospital to ICU admission. The impact of
extensive lung infiltrates in our study supports a major
role for hypoxemia in loss of graft function. The deleter-
ious impact of later ICU admission on graft survival (but
not on patient survival) also deserves attention. Prompt-
ness of diagnosis and treatment is crucial to successful
treatment [41]. Factors that may contribute to explain-
ing graft loss include bacterial infection with septic
shock, cardiogenic edema with a possible alteration
from hypertension to hypotension and drug toxicities.
Our results support early ICU referral of renal trans-
plant recipients with ARF.
Both FO-BAL and noninvasive tests were useful in
identifying the cause of ARF in our study. Immunofluor-
escence performed on induced sputum yielded the diag-
nosis of P. jirovecii pneumonia in three patients. Blood
cultures were often positive as many patients had bac-
terial pneumonia and ALI or ARDS complicating extra-
pulmonary (mostly urinary) bacterial infection. Similarly,
echocardiography was often informative. The substantial
diagnostic yield of FO-BAL supports the first-line use of
this procedure until more data on noninvasive tests
become available. Also, given the effectiveness of nonin-
vasive tests, we recommend adding them to the stan-
dard diagnostic strategy.
Our study has several limitations. First, we used a ret-
rospective design. However, data collection was done
specifically for this study and by the same investigator
(EC) in the nine centers. Second, we included patients
over an 8-year period, during which changes in treat-
ment practices probably occurred. For instance, at ICU
admission, 86.7% of our patients were on corticosteroid
therapy. The use of newer immunosuppressive agents
such as sirolimus, mycophenolate mofetil, T-cell and
B-cell depletion and costimulatory blockade has led to a
substantial number of patients being treated without
long-term steroid therapy [6,19]. Third, one-fourth of
our patients had cardiogenic pulmonary edema, in keep-
ing with the high rate of cardiovascular comorbidities.
Pulmonary edema does not require invasive diagnostic
procedures and differs in itso v e r a l lm a n a g e m e n tf r o m
other causes of ARF. However, cardiogenic pulmonary
edema may occur concomitantly with infection. More-
over, the aim of our study was to provide clinicians with
data relevant to their everyday practice. Therefore, we
included patients with ARF due to cardiogenic pulmon-
ary edema. The strengths of our study include the mul-
ticenter design, including nine participating transplant
centers, all of which had extensive experience with
managing medical complications in kidney transplant
recipients. Furthermore, the participating ICUs had con-
siderable experience in managing immunocompromised
patients with ARF [28,42,43].
Conclusions
In summary, medical complications requiring ICU
admission occurred in 6.6% of kidney transplant recipi-
ents, and ARF accounted for one-half of these admis-
sions. Bacterial pneumonia, cardiogenic pulmonary
edema, and ALI or ARDS related to extrapulmonary
sepsis were the leading causes of ARF. Pneumocystis
pneumonia was common and severe. By day 90 after
ICU discharge, mortality was 22.5%, 20% of the
patients had lost their transplant and only 37.5% of
patients had recovered their pre-ICU renal function.
Patient survival correlated with acute illness severity
and the cause of ARF. Graft survival correlated with
previous graft function, pulmonary disease severity and
the cause of ARF. Our data suggest that extended che-
moprophylaxis for bacterial and fungal infection and
early ICU admission of patients with ARF may
improve outcomes.
Key messages
￿ Acute respiratory failure accounts for one-half of
the ICU admissions in recipients of kidney
transplantation.
￿ 90-day mortality is 22.5%, but a one-fourth of sur-
vivors have lost their graft.
￿ In the early posttransplant period (< 1 month) car-
diogenic pulmonary edema accounted for one-half of
the diagnoses, while opportunistic fungal infections
and drug-related pulmonary toxicity were mostly
diagnosed in the late posttransplant period (> 6
months).
Canet et al. Critical Care 2011, 15:R91
http://ccforum.com/content/15/2/R91
Page 8 of 10￿ Fiberoptic bronchoscopy and bronchoalveolar
lavage led to the diagnosis in 45.5% of cases.
￿ Diagnoses of bacterial or opportunistic fungal
infections are associated with in-hospital mortality.
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